drugset / Trial / NCT00000234

Alternate Day Buprenorphine Administration, Phase XI - 16

NCT00000234

CrossoverTreatment

Summary

The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified

Indications